Brought to you by 
Pfizer, Akzo Nobel's Organon develop antipsychotic drug
23 May 2012
Executive Summary
Akzo Nobel's human healthcare subsidiary Organon USA and Pfizer entered into an exclusive worldwide development and commercialization agreement for Organon's asenapine for schizophrenia and bipolar disorder.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer, Akzo Nobel's Organon develop antipsychotic drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice